A good piece by Dan Satherley on Newshub:
Health law expert rips into TPP
The recently signed Trans-Pacific Partnership (TPP) will “dramatically” restrict access to affordable medicine in every country that ratifies it, according to a US law expert.
Writing in scientific journal PLOS Medicine, Professor Brook Baker of the Northeastern University School of Law in Boston argues the TPP will:
- lead to more patents being placed on new medicines
- extend the length of new patents
- restrict access to clinical trial data
- prevent the introduction of new generic medicines
- toughen penalties for patent infringements.
“Buried in 6,000-plus pages of text, annexes, and side letters, there are multiple provisions — complex in their articulation, but simple in their effect: they dramatically increase monopoly protections for the transnational originator pharmaceutical industry,” he writes.
He cites a US$500 million claim brought against Canada by a pharmaceutical company after the government there revoked patents on two medicines the courts ruled didn’t meet the standards of patentability. “Canada will have to spend millions of dollars to defend against this claim even if it ultimately wins, which is likely,” writes Prof Baker. … “TPP member states can expect an avalanche of IP-related claims from disappointed pharmaceutical companies that think their legitimate expectations of future profits have been thwarted.”